Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95843
UPID:
GUC1C_HUMAN
Alternative names:
Guanylate cyclase activator 1C
Alternative UPACC:
O95843; O95844; Q9UNM0
Background:
Guanylyl cyclase-activating protein 3, also known as Guanylate cyclase activator 1C, plays a pivotal role in visual signal transduction. It modulates guanylyl cyclase 1 (GC1) and GC2 activity in response to changes in free calcium ions concentration, facilitating the recovery of rod photoreceptors to the dark state after light exposure.
Therapeutic significance:
Understanding the role of Guanylyl cyclase-activating protein 3 could open doors to potential therapeutic strategies.